RNA Therapeutics: An Overview
By Rajaneesh K. Gopinath, Ph.D. For ages, the biopharmaceutical market has been dominated by small molecules that predominantly targeted cellular proteins. And yet, a majority of them have been undruggable. …
Read MoreThe Next Generation Biotech Media
By Rajaneesh K. Gopinath, Ph.D. For ages, the biopharmaceutical market has been dominated by small molecules that predominantly targeted cellular proteins. And yet, a majority of them have been undruggable. …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Alnylam Pharmaceutical’s GIVLAARI™ (givosiran) became the second-ever RNA interference-based drug to bag the FDA nod. The RNA interference (RNAi) phenomenon discovered by Andrew Fire and …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. The IL-5 receptor alpha binding monoclonal antibody, FASENRA® (benralizumab), is a prescription medicine used in combination with other asthma drugs to control severe asthma. With the latest …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. The Swiss drug maker announced positive results from studies belonging to its PLATINUM Clinical Development Program that tested two inhalable asthma drug candidates. The drugs …
Read MoreEndometriosis is the condition where the endometrium-like tissue grows beyond the uterus, and abnormally adheres to the ovaries, peritoneum, colon, bladder, and ovarian ducts. These abnormal tissues share many qualities …
Read MoreBIO Asia, first time in Taiwan, co-organized by Biotechnology Innovation Organization (BIO) and Taiwan Bio Industry Organization (Taiwan BIO), has kicked off in Taipei on July 24th with the Conference, …
Read MoreCStone and Bayer Collaborates to Evaluate Combination Therapy with PD-L1 Monoclonal Antibody CS1001 and Regorafenib On June 10th, CStone Pharmaceuticals and Bayer HealthCare announced global collaboration to evaluate PD-L1 monoclonal …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. In a major breakthrough, researchers from the University of British Columbia in Vancouver, identify an enzyme pair from an obligate anaerobe through their functional metagenomic …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. This is Merck’s third oncology company acquisition this year, after Immune Design and Peloton Therapeutics. On June 10th, Merck & Co. announced its decision to …
Read MoreProstate cancer is the fourth leading cause of death from cancer in men world-wide according to a report released by the International Agency for Research on Cancer (IARC) in 2018. …
Read More